Image source: The Motley Fool.
Ligand Pharmaceuticals Inc (LGND -0.07%)
Q1Â 2020 Earnings Call
May 6, 2020, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Hello, and welcome to Ligand's First Quarter of 2020 Financial Results and Business Update Conference Call. My name is Catherine, and I will be your event specialist today. [Operator Instructions] And please note that today's webcast is being recorded. [Operator Instructions]
It is now my pleasure to turn today's program over to Patrick O'Brien, SVP, Investor Relations at Ligand's Pharmaceuticals. Patrick, the floor is yours.
Patrick O'Brien -- Senior Vice President of Investor Relations
Thank you, Catherine, and welcome, everyone. Consistent with recommendations for social distancing, all of our speakers for today's call are in separate locations. So we apologize in advance for any background noise or technology difficulties that we might run into. Speaking for Ligand today will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO. We will be using slides to guide our discussion today. We will also use non-GAAP financial measures, and some of our statements will be forward-looking. Additional information concerning risk factors and other matters concerning Ligand can be found in our Ligand's earnings press release, slides and periodic filings with the SEC. Ligand undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.
I would now like to turn the call over to John Higgins.
John L. Higgins -- Chief Executive Officer
Thank you, Patrick, and good afternoon, and thanks for joining our call.
These past few months have been an extraordinary period, unlike anything any of us has ever seen in business. The COVID-19 pandemic has created some extreme challenges for companies. Yet, all things considered, I am pleased to report that Ligand is doing well. We have a set of slides to go with our presentation today, and I'd like to start with slide four as just the backdrop. We talk about Ligand and how our innovation is driving value. There are three main focuses of our business or elements of our business we focus on: technologies that underline our partnerships; our portfolio; and financial growth. We believe we can run a successful business by being dedicated to extraordinary customer service. And in times like these, that could not be more true. And finally, our team. We've got a fantastic team, and I'm so proud of what they are doing. Before I go any further, I just want to make a few remarks, given the current environment. Our Ligand team is highly talented. We're deeply committed that in a team that has adapted very well to the current business environment. We're making good progress with our internal programs and advancing new licensing deals, and we recently closed an important new acquisition of Icagen.
Notably, we are devoting an intense amount of time and work to support our partners' needs for the scale-up and manufacturing of remdesivir. I'm proud of our team and very inspired by their efforts for going above and beyond in all they do. It is strengthening our company in an otherwise very difficult period. As for my business commentary, I will frame my remarks in context of the pandemic. We're in uncertain times, and we're operating in a world defined by restrictions no one planned for or even thought possible. On balance, we are very pleased with the financial report we have today and believe we are relatively well positioned. First, I'll provide a summary about our ongoing operations and work at the company, then I will cover our partnered programs and our assessment for how our programs and our partners are holding up. And finally, I will briefly touch on our contributions to remdesivir. I would now like to turn to the business highlights this past quarter, and we'll take a look at slide five. Our internal operations and ongoing programs are mostly unaffected by the pandemic. We decided to delay the start of our Phase II iohexol clinical study after consulting with our experts and advisors, but we still expect to report data next year. As I mentioned, we advanced internal research programs, we closed an important new acquisition of Icagen and completed several new licensing agreements with our new R&D partners. On all these fronts, the business productivity feels like any regular quarter of operations. We are pleased to have kept the momentum moving forward.
Now when we look to slide six, just some general remarks in light of the current environment. First and foremost, we have a very strong balance sheet and strong cash flow. And we do not foresee any COVID-19-related layoff. As Matt Korenberg will discuss, our revenue mix will change with an expectation now for lower royalty and contract revenue that's more than offset by higher capital revenue. As he'll discuss, we are raising 2020 guidance for total revenues and diluted earnings per share. We expect to emerge from these challenging times with our long-term profitability in equal or better standing. Royalty revenues should recover as patients are able to more freely access their important treatments again. And while we see delays and postponements to some of our contract payments, we generally do not see them as lost payments. At this time, it seems more the case they're simply pushed out a couple of quarters. Now we'll turn to slide seven. The fact that we believe Ligand can emerge in a strong position speaks to our business model. We are committed to innovation and to serving the industry. Our customers are pharma and biotech companies. And more than ever, the world is learning the value this industry provides. Medical research is not a luxury. It's a necessity for a modern civilization. Ligand is an important part. We help assist the vital research our partners are pursuing to get answers and make drugs possible.
When we look to slide eight, this is a diagram we introduced a couple of months ago. It's a simple chart, we call it a bull's eye diagram, but it shows, by our technology platform, how our partnered programs, our shots on goal, are arrayed. Each white dot represents a fully funded program by one of our partners. You can see OmniAb, the antibody segment of our business, is the largest segment. We have a very substantial portfolio partners in our Captisol unit. And we have several other technologies that have come through acquisitions in the last year or two that are also driving partners. Obviously, the outer ring, that defines the preclinical segment. About half of our programs are early stage. That's not a surprise. These are discovery programs or research concepts that are being tested in early stages. But as you move toward the center, we have a nice migration of assets that are matriculating into Phase I, Phase II, Phase III, and now the largest concentration of NDA stage or marketed programs in our history. We're excited about this diagram and believe it succinctly illustrates the breadth and the substance of our portfolio.
When we look to slide nine, I would now like to turn to some specific comments about our pipeline. Ligand is focusing on investing in research and technology to support our programs. And again, we have over 125 partners who are funding over 200 fully funded programs. Now when the pandemic hit, we knew it could possibly have a major impact on our partners. So we reached out to every one of them to assess the impact on their business and more specifically the impact on our partnered programs, to see if we could offer any assistance and to understand a little bit better if there would be delays or an impact to our programs. Now we received a response from almost every company, and we are very pleased with our findings. For starters, we have a range of partners, public and private, large and small. Investors who follow us know that this portfolio, it largely reflects the industry. As you can see here, we have about 40%, 43% are small biotech pharma companies, about 1/3 are start-up private and then about 15% to 18% are large pharma or biotech. The ownership, about half are private and half are public.
When we look to slide 10 and 11, this is where we can get into a little more of the substance of our findings. We found that, overall, the impact appears to be minimal, reported out. We asked about impact on employees, if there's going to be a downsizing or an operating stat, and would the closures to laboratories or facilities impact business. And half said no impact and another quarter said a minimal impact. We were very pleased to hear that because we know in certain industries, even certain companies within our industry, there has been a devastating loss of continuity of business. We're seeing 5% to 10% have what they're rating today as a significant impact. But in conversations, we're hearing that, that impact may resolve itself over the next couple of quarters. In terms of capital position, nearly 3/4 are very strong. They're public companies. They're well capitalized. They have a strong financial reserve or a clear line of sight on capital. About 1/4 has the belief that they'll have a need to finance in the next 12 to 18 months. As the economy recovers and move through this, we think that their access to capital will resume.
On slide 11, just a final comment about this survey, and again, it is our window into the industry, and we think it's helpful, not only for us, as a company, to plan, but also to our investors in terms of understanding how a large portfolio might be represented. This slide 11 shows the impact on development stage programs. And again, this is going beyond the operations and impact on employee structure. This is specifically our programs. Again, half of the companies have reported no impact on Ligand-funded programs at all and another 20% have only a small impact. And as we look at the small slices of this pie, there's a few slices in the 5% range that are measuring either a suspension or a significant impact. Obviously, we're monitoring those. But in the overall portfolio, our sense is that, at most, 5% to 15% of our programs will have a material impact that could delay the programming by a couple of quarters. On balance, all things considered, we are very pleased and relieved by these findings.
Now we'll just turn to slide 12 as a backdrop. We have a lot more to discuss on this call, but I would like to offer a word about our COVID-19-related programs. First, as Investors know, we are not in any viral company. But given our drug-enabling Captisol technology, we are now involved in one of the most important antivirals in development. It's our focus on research and innovation that provides cutting-edge technology either to help discover drugs or to make drugs possible. The fact that we're deeply involved with programs targeting COVID-19 is not a surprise. Companies are coming to us to make their drugs possible. We are living in what is arguably the biggest health crisis in the past century. Ligand can help. And so it follows that companies will come to us for solutions. Over the past two decades, we've been involved in some of the most important medicines on the planet, drugs to treat cancer, drug to produce platelets, super potent antibiotics and antifungals. And now we're providing technology to Gilead for their important new antiviral for COVID-19. Some have asked us, how does this come to be? And the answer is simple. This is Ligand. We are there to help make drugs possible or to make them work better.
Global partners like Gilead come to Ligand because we have the capacity, the consistency, quality, an FDA-certified safety record for an excipient that is required to formulate chemicals to make them a viable drug. No other company provides Captisol. We stand out among all other cyclodextrin suppliers. You see without Captisol, some drugs would not be possible, they are not soluble. They are insoluble. They do not dissolve in water for subsequent use by the human body. Put into water without dissolving, the active ingredients result in a cloudy mixture. This is the case with remdesivir as it is with many of our partners' drugs. But Captisol addresses that. It elegantly solubilizes the drug into a crystal clear solution. It becomes a compound ready to be tested for human use. Matt Foehr will discuss more of the chemistry and share the photos with you. As background, Gilead reported data last week that out of two clinical trials, two things were learned. One, that remdesivir appears to shorten time to recovery; and two, when treating patients with severe disease, a 5-day treatment course is potentially as effective as 10 days. Following the announcement of top line trial results, the FDA very quickly issued an Emergency Use Authorization for remdesivir as the first new treatment for COVID-19. Gilead is now ramping up production. We are closely aligned with them, and we will make it a top priority to ensure we can provide everything they need to meet their production requirements.
As Matt Korenberg will discuss, we expect Captisol revenues to be higher in 2020 than our original outlook given Gilead's stated production goals. And if the ongoing trials continued to support use of remdesivir as a treatment and Gilead achieves the production goals they have publicly stated for 2021, then we expect, in order to meet that continued production ramp, that Ligand will supply additional Captisol in late 2020 and also into 2021. This would be amounts above the levels already included in our outlook today, and we will require significant investments in capital equipment and the supply chain to allow us to meet the increased demand. We will follow Gilead's lead and stay ready to supply more Captisol as they need it. We will monitor the situation and seek more clarity and certainty on production requirements as time moves on.
We'll move to slide 13. As a quick comment, I want to acknowledge our Board of Directors. It's a diverse team. We recently added Sarah Boyce as our eighth independent director. This team, they have outstanding scientific and business experience, working closely with management to help drive our business. We have former leaders of some of the world's largest pharmaceutical companies on our Board. We have antibody experts. We have strong business operators. These are people who understand the challenges and risks this industry faces, and have been very helpful and supportive as we plan and manage through the current environment. As a last comment, I want to close by saying, we know there is a vast humanitarian need due to the coronavirus, and we are humbled to be able to contribute to that. We are redirecting our people, our capital and other resources to rise to the challenge. Gilead's work on remdesivir has given the world a beacon of hope. Ligand's team is there, too, supporting them. Despite the pandemic, we have reasonable clarity into our future. By sticking to innovation, staying focused on excellent execution and partner support and by relying on our people, we believe we have a well-balanced business and are positioned to meet our partners' needs and continue to build value for shareholders.
With that, I'll turn it over to Matt Korenberg to comment about our financial performance.
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Thanks, John. The first quarter of 2020 was a fantastic quarter for Ligand with strong financial performance driven by our Captisol material sales. For the quarter, total revenues were $33.2 million, with significant growth of our continuing royalties and a sizable increase in Captisol material sales. Similar to our Q4 report three months ago, royalties again grew nicely, up 23% year-over-year in Q1 2020 versus Q1 2019, excluding Promacta. Adjusted EPS was $0.89 or $0.40 higher than Q1 2019, excluding Promacta. In addition, we generated about $17 million in cash flow from operations in Q1 2020. Our revenue and cash flow generation exceeded our expectations.
In addition to the strong business performance in the first quarter, we used our balance sheet to close one acquisition and to opportunistically repurchase both stock and convertible bonds. On the convertible front, we retired over $234 million of face value bonds for approximately $203 million, thereby saving about $31 million of cash that we otherwise would have been required to repay toward the principal amount of the notes in May of 2023. On the common stock side, in Q1, we spent $73 million on share repurchases, retiring an additional 878,000 shares. We currently have about $253 million remaining on the $500 million share repurchase authorization that we have in place. As we'll disclose in the 10-Q when filed, we now have about 16 million shares outstanding and, at recent stock prices, about 16.5 million to 17 million fully diluted shares outstanding.
We finished the quarter with $739 million of cash, cash equivalents and short-term investments. In addition to the capital structure and capital return, we remain focused on identifying acquisitions across several types of target companies. Digging now a little deeper into the Q1 performance on revenue. Total revenues for the first quarter of 2020 were $33.2 million and included $6.6 million of royalty revenue, $21.1 million of Captisol sales, $3.4 million of service revenue and $2.1 million of contract revenue. With respect to royalties, Kyprolis and EVOMELA drove the 23% year-over-year growth that I mentioned. The Captisol sales increase was driven by sales principally related to remdesivir. And our new service line, which I'll discuss on the next slide, performed in line with our expectations for the quarter.
Lastly, the contract revenue line in Q1 2020 included the typical flow of annual license fees and smaller milestones, while Q1 2019 included significant milestones related to an approval of financing in several clinical trial starts. As I just touched on, on slide now looking at slide 17, we're now reporting our revenue in four line items instead of 3. We're now splitting out the milestone and license fee line into two buckets: Service revenue, represented in the burnt orange color on the graph; and contract revenue, represented in the brighter orange color. Upon the consummation of our Icagen acquisition, we felt it was important to share with investors the substantial portion of the old milestone line that comprises this very visible, predictable line item we are now calling service revenue. As
You can see from the graph, the line has grown significantly over the past several years with our acquisitions of Crystal Bioscience, Vernalis and now Icagen. We'll include the majority of the near-term revenue related to these business lines in this line. Once the program is fully turned back over to our partners and Ligand has no further involvement, any future revenue generated will fall into the contract revenue line and eventually the royalty line. Historically, we've discussed our portfolio of more than $3 billion of potential milestones. We always remind investors that not all of the revenue not all of that revenue will be realized as drug development is very challenging, and most, but not all, programs fail in the clinic. However, even accounting for anticipated failures, we expect that the new milestone and license fee line will result in an average of $20 million to $40 million per year in the near term, with growth seen in that line over the longer term as the portfolio matures and later-stage milestones are realized. It will not always be in this range. Some years could be higher and some could be lower. In fact, as we turn to guidance on the next slide, you'll see that we're now expecting below $20 million in 2020 due to the COVID-19 impact. Now quickly I'll quickly dig deeper into each of the four revenue line items describing our most recent previous guidance, the impact we're estimating from COVID-19 and our new estimated contribution to guidance.
Starting with the royalty line. Our original guidance for 2020 was $38 million. After seeing Q1 reports from our partners, we now expect about 15% lower royalty, or $32 million. We estimate the largest negative impact to Ligand revenue from COVID-19 will be our contract revenue. At the start of the year, we estimated about $30 million for this line item, and we now estimate approximately $18 million or down 40% as partner clinical progress is delayed. Service revenue remains largely unchanged. Going into the year, we saw about $25 million, including the Icagen acquisition, of service revenue across the three business lines. After Q1, well, we still expect about the same. These contracts with our customers tend to be longer in nature and more predictable. Despite stay-at-home orders impacting all of our facilities, our labs are able to stay open on a modified basis to allow important scientific work to continue.
Lastly, on Captisol sales. Our original estimate for the year was $35 million. We're now including $65 million of Captisol sales in our guidance for the year. As John already mentioned and as Matt Foehr will give some more detail on, our ultimate Captisol revenue for the year will be highly dependent on the ability of Gilead and the rest of the supply chain to make progress on the estimates for production that Gilead has given for courses of treatment produced this year. Turning to slide 19. These revenue components that I just went through all translate to $140 million of total revenue for 2020, up from our previous guidance of $133 million. On the expense side, we expect an overall corporate gross margin of approximately 85% to 90%. For R&D, we now expect $50 million to $54 million of total expenses for the year. Excluding stock comp and other noncash charges, we expect that R&D cash expenses will be $33 million to $35 million. For G&A, we expect total expenses of $37 million to $39 million. And excluding noncash charges and stock comp, we expect G&A cash expenses to be approximately $21 million to $23 million. Together, we expect cash operating expenses for 2020 of $55 million to $58 million. And these cash expense estimates factor in about $2 million of cash expense savings we've identified as a result of COVID-19.
Related to interest income and other income, we continue to maintain our cash and highly liquid short-term investments. Our realized interest rates continue to fall with the overall market environment. Given the lower expected yield and the reduction in our cash balance from retiring some debt, which is offset by the interest expense saved, we expect cash other cash income of about $13 million to $15 million, down from our original guidance of $17 million to $19 million in 2020. These revenue and expense components all translate to full year 2020 adjusted earnings per diluted share of approximately $3.65, which is up 45% from the 2019 number of $2.52 if you adjust for the Promacta sale and then and also represents an increase from our previous guidance of $3.62.
On my final slide before I turn the call over to Matt, I'll touch quickly on the capital deployment front. As we've seen, we'll continue to evaluate opportunities as we have been. We'll continue to evaluate opportunities to augment our operational financial results by evaluating ways to return capital to our stockholders and other strategic transactions. We remain focused on identifying acquisitions across four areas of investment. Our shopping list includes some larger names that add major technology platforms as well as revenue and partnered programs. We also are evaluating a number of technology tuck-ins that augment our leading platforms and several product financing ideas that can contribute to the story in the near term. With $739 million of current cash, we believe we have sufficient funds to execute on our strategy.
Finally, I'd just direct listeners to review our Q1 earnings press release issued earlier today and available on our website for a reconciliation of our adjusted financials to GAAP reported items.
With that, I'll turn the call over to Matt Foehr for some comments on our portfolio and pipeline. Matt?
Matthew W. Foehr -- President and Chief Operating Officer
Thanks, Matt. So I'll start with slide 22, and slide 22 shows a traditional snapshot of a portion of our partnered pipeline that, as John already described, is diverse and growing. It's our technologies that form the foundation of the portfolio at Ligand. And this afternoon, I'll review some of our technologies, specifically highlighting the Vernalis design platform, or VDP, and Icagen, our OmniAb platform and then our Captisol technology. Starting with VDP and Icagen. Our team in the U.K. joined Ligand just 18 months ago, and we've been very pleased with their progress and their productivity. We recently entered a license deal with a start-up called Neuritek Therapeutics for a VDP molecule called V158866. 866 is a novel oral selective fatty acid amide hydrolase, or FAAH inhibitor, and Neuritek plans to develop the drug for post-traumatic stress disorder and other CNS diseases. We received an upfront license fee and are eligible to receive a financing-related milestone, development and commercialization milestones of more than $240 million and tiered royalties on sales ranging from 6% to 8%. At the end of Q1, Neuritek announced that it secured approximately $27 million in capital commitment from the Gem Group, which we think positions them well for entering a Phase II trial in PTSD within the next few quarters. Neuritek is also currently pursuing a public listing in Europe.
It's also been a busy time as we've welcomed and integrated our new colleagues from Icagen following the closing of that acquisition in early April. We're pleased to say that the integration of Icagen has gone extremely well, and that's a testament to both the Ligand and Icagen teams. With Icagen, we added some fantastic new colleagues with unique expertise, along with great technology and high-value partnerships with Roche, the Cystic Fibrosis Foundation and a number of others. And we expect that the ion channel technologies of Icagen could help drive new deal-making in the future. slide 23 gives a summary of how we see these technologies fitting together. The culture and the team at Icagen fits seamlessly into Ligand, and their ion channel technologies marry perfectly with Vernalis' expertise in fragment-based drug discovery as well as with downstream elements of OmniAb when partners are pursuing high-value and complex ion channel targets.
Moving now on to slide 24. OmniAb continues to be the best-in-class of cutting-edge antibody discovery tools. Our team of scientists continues to further innovate OmniAb's various platforms, and our M&A team continues to make OmniAb even more valuable through bolt-on acquisitions. As is shown on slide 24, there are now more than 80 OmniAb-related shots on goal in Ligand's pipeline in various stages of discovery or development. The number of active or recently completed clinical trials that include an OmniAb-derived antibody reached 43 recently, with new clinical trial starts in Q1 that included two new Phase I or Phase Ib trials, three new Phase II trials and two new Phase III trials. We also saw new INDs filed as well as OmniAb's first regulatory filing for commercial approval. Partners understand OmniAb's best-in-class status and the value of collaborating with our science team as they work to discover novel antibodies.
I will note that as John generally mentioned, we've been working with a global multinational partner on a program for antibodies derived from our OmniChicken platform for treating COVID-19. We obviously highly prioritized that program's activities in Q1, and the work is very early, but it's progressing very well. And now I'll update on Captisol. Before discussing Captisol's role in support of Gilead's drug, remdesivir, I want to call attention to the upcoming virtual ASCO meeting and mention that we are expecting to see data on many Ligand partner programs at this year's meeting, specifically three Captisol programs that will have clinical data at ASCO, including Amgen's Kyprolis, which uses Captisol in its formulation; Amgen's innovative BITE molecule, AMG 330; and Takeda's pevonedistat. The latter program will have new data in patients with higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia or low blast acute myelogenous leukemia. We look forward to seeing these and other presentations of data from Ligand partners. And now, more generally, about Captisol on slide 25. We've seen steady growth in Captisol in recent years. And as Matt reviewed, we project significant growth in 2020. We've invested in our drug master files in the U.S., Canada, Japan and China, and those investments have been important to our partners. slide 26 summarizes Captisol's key differentiating features, which include our global reach, our know-how, our intellectual property, the drug master files, as I just mentioned, and our manufacturing, quality and scale. Partners also appreciate that Captisol now has a 5-year shelf life.
Moving to slide 27. I note that we've invested significantly in supply chain integrity for Captisol over the years, qualifying two manufacturing plants and distributing out of five facilities strategically located around the world. We've invested in the supply chain in a comprehensive way, going all the way back to our sourced materials, including keeping safety stock of raw materials, qualifying multiple vendors with whom we have had excellent and long-standing relationships. That approach to our supply chain positioned us to be able to respond very quickly to large orders in the first quarter and to further ramp up production, which is an ongoing process. Captisol is a highly complex technology. Yet it is a proven technology platform that is used in a number of life-saving medicines that are helping patients globally. Captisol is generally used at concentrations far in excess of the active ingredient, as is highlighted on slide 28 and as is described in our partners' product labels. Because of that, we've always taken our role as a high-quality and reliable partner and supplier very seriously. That's also part of why supply chain integrity, quality and reproducibility, backed up with safety and toxicology data in our drug master files, have been, and will continue to be, very important to us and to our partners.
And you will see on the right-hand side of slide 28, the range of Captisol concentration ratios used for some of the commercial products that use Captisol. Last week with Gilead receiving an Emergency Use Authorization for remdesivir, formulation ratios were disclosed as 30:1 for a lyophilized powder form of the drug and 60:1 for an injection solution form. So there's a range of use, and there's also obviously a range of doses that have been evaluated clinically. We can't go into finer detail than what's on the slide or already in the public domain so as not to disclose confidential partner information, but I will say that the potential scale of Captisol needed for remdesivir is larger than for any other current commercial or clinical product that's formulated with Captisol. This is triggering capital investment related to highly specialized and custom equipment on our part, but we're well positioned to make those investments throughout the year.
Our Captisol partnership with Gilead for remdesivir is a strong one. It dates back to December of 2015 when Gilead was developing the drug for Ebola. The next couple of slides contain some data from laboratory studies or demonstrations or computer molecular modeling analyses that help illustrate, on a more scientific level, the role that Captisol plays in formulations. This is similar to the role that it plays with many of the products that are either available to patients today or are under development. And you see on slide 29, a snapshot of molecular dynamics modeling show the insertion of the remdesivir molecule in the Captisol cavity, which is shown predominantly in purple and has the more circular structure. These are analyses that are commonly performed and discussed at formulation and technical meetings when evaluating Captisol. slide 30 is an even more simple visual representation, illustrating the role of a 30:1 ratio using Captisol and the impact it can have in dissolving 100 milligrams of remdesivir. These sorts of demonstrations and visuals are quite common and have been reported and documented publicly.
Finishing up now, slide 31 has photos of our facilities that support our major technology platforms, with Icagen there on the right being the new addition to our technology base. I also want to take a moment to acknowledge the work and dedication of our employees and especially the team managing our Captisol technology. They've worked tirelessly day and night over recent months to ensure reliable supply of Captisol, and they're also doing a lot of planning for the future. Their work is very important, and they know that. They work each day with a clear sense of urgency and responsibility, and I want to thank all of them for that. And I also want to acknowledge our partners at Gilead. It's no understatement to say that their work and their progress is being watched by the world. We spent a considerable amount of time interfacing with the global supply chain team at Gilead over recent months. And their professionalism, their organization, their efficiency, their collaborative working style are second to none. They are truly a world-class organization, and we're honored to be working with them in supporting their needs for Captisol.
And with that, I will turn the call back over to our operator for questions. Operator?
Questions and Answers:
Operator
[Operator Instructions] Your first question is from the line of Matt Hewitt. Your line is now open.
Matt Hewitt -- Craig-Hallum Capital Group -- Analyst
Good afternoon and congratulations on the strong quarter and everything that you're doing. We appreciate everything that you're doing to help Gilead, obviously, given the uncertainty right now. A couple of questions, I guess, related to the Captisol. The first one, the company has talked about, in the past 24 hours, about looking for partners internationally to help on the distribution and on the manufacturing front. And I'm just curious, how does your contract with Gilead affect your ability to contract with those partners? Or just kind of walk us through that situation, please.
Matthew W. Foehr -- President and Chief Operating Officer
Yes, Matt, this is Matt Foehr. As I said, we've got a fantastic partnership with Gilead. We are very aligned with them in the global planning. Our relationship with them was struck back in 2015. It is nonexclusive and permits us to supply others. But as I said, we're aligned with them as they roll this out, both in the U.S. and globally.
Matt Hewitt -- Craig-Hallum Capital Group -- Analyst
Got it. All right. And then and I don't know if this is possible, but is there a way to break out the contribution from Gilead versus your other partners? Not I don't not you don't need to get into the specific components other than if we could get what the Gilead component is versus the others, that would be helpful.
Matthew W. Foehr -- President and Chief Operating Officer
Yes, Matt, I'll comment, and then Matt Korenberg may want to comment as well on the financials. Generally, we don't break down partner by partner. That's not something we've done previously. Obviously, when we originally increased guidance around Captisol, we attributed that to supply for remdesivir. So there's that. And obviously, we've made those statements publicly. I don't know if Matt Korenberg may want to add as well.
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Yes. I think that's right, Matt. I think it's fair to say that the bulk of the increase in our guidance on the Captisol side, both originally and now, are largely tied to the Gilead remdesivir sales.
Matt Hewitt -- Craig-Hallum Capital Group -- Analyst
Okay. That's helpful. And then quick question on the Matt Korenberg, maybe you could on the royalty side. Kyprolis numbers are, obviously, just from Amgen, but they came out, were very strong. We don't have oh, no yet, but even if that's flat, you've got a really strong first quarter for that product. Is the lower guidance, is that a function of some of the others? Or is there some anticipation that maybe Kyprolis flatlines over the course of the year? Just help us understand what were the moving parts were there?
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Good question, Matt. And it's important to note that we don't have control over any of the sales. So we really are estimating the impact of COVID-19 on the remainder of the year across all products, but specifically with Kyprolis and EVOMELA, the two largest contributors. What we've estimated, without any input or knowledge really from our partners. But what we've estimated is that the impact in Q2 we felt the most. So we are estimating a decline in Q2 and then a return to sort of normalcy toward the back half of the year in terms of scripts. Obviously, as you pointed out, Q1 for Kyprolis was the best quarter they've ever had or close to the best quarter they've ever had, a very strong one. So it certainly is possible that we are being conservative, but we're just doing our best to estimate what's going to happen with the slowdowns and stay-at-home orders for the rest of the year.
Matt Hewitt -- Craig-Hallum Capital Group -- Analyst
Understood. Okay. Maybe one last one for me. There has been talk here recently about Gilead seeking additional form factors for remdesivir, obviously, the IV solution. It's great to have a treatment, but it's not ideal that it's IV. They've publicly commented, I believe, about seeking alternatives. Maybe walk us through whether or not Captisol plays a role beyond the IV solution.
Matthew W. Foehr -- President and Chief Operating Officer
Yes, Matt. Thanks. This is Matt Foehr. Captisol, the safety database has been built up over many years, IV data, oral solutions, inhalation, subcutaneous, a variety of forms, and that's all been put into our drug master file over time. When a molecule is insoluble, generally, it's going to need that solubility and delivery technology for other modes of delivery as well. And we've got a long history of generating data in inhalation formats and others. So when a molecule has solubility issues, it's going to need a solubility solution like Captisol. And Captisol is well suited to provide those sorts of solutions.
Matt Hewitt -- Craig-Hallum Capital Group -- Analyst
That's great, thank you very much.
Operator
Your next question is from the line of Balaji Prasad. Your line is open.
Balaji Prasad -- Barclays -- Analyst
Hi, good afternoon and thanks for taking my questions. Firstly, I have to call out your statement on the fact that you're not laying off a single employee on the back of COVID. So congratulations on that.
So I have a few follow-up questions on Captisol itself. Well, firstly, while we are conscious of what this means for 2020 and Gilead, I also want to take a step further ahead and see how should we think about recurrence of Captisol sales in 2021 or beyond that? Are you seeing greater inbound calls for partners seeking to look to tie up with Captisol? And maybe I'll start with that and follow up further.
Matthew W. Foehr -- President and Chief Operating Officer
Yes, Balaji. This is Matt Foehr. Yes, absolutely, we're seeing increased inbound calls for Captisol. Captisol is obviously a well-established technology. Remdesivir is obviously a very high-profile drug. But yes, we are seeing increased inbound. As we look out, part of the reason why we're comfortable making capital investment is that as we look ahead, we see the need, and that's part of the reason we're making the investments we are.
Balaji Prasad -- Barclays -- Analyst
Fantastic. And...
John L. Higgins -- Chief Executive Officer
This is John. I'll just add a little more color, Balaji. I appreciate the question. On the earlier question that Matt asked, but it's somewhat related, as we've described, we are truly following Gilead's lead, and that's important for everybody to understand that they really are driving the planning around this. But we are there with them very, very closely. And over the last day or 2, we've seen the announcements that they are working on an international coalition of partners to help them plan and produce. We will be with them as they coordinate that. And it's not only ensuring that there's drug to manufacture, but that all the elements are brought together responsibly and in an organized manner. So we can all imagine the complexity of doing this, but Gilead is driving this, and we are right there with them. And so as companies are calling us, these other parties around the globe, and want to participate, we are getting those calls. We are very active in those discussions. But ultimately, again, this is being quarterbacked, if you will, by Gilead.
The other element of this is that Gilead, we think, responsibly, is describing the challenges, but how they've risen to the challenge to deliver very substantial quantities of drug, and they're trying to give a road map for what they believe they can produce this year and then in the next year. They've had a range of public statements and there's commentary on their website, their goal to have a certain amount of courses produced by the end of this year and then even more, multiple of that quantity, potentially in 2021. Given the fact they are describing this as a six month lead time to manufacture, of course, they have to get their materials in order, and we have shipped them a substantial quantity of material so far and, obviously, that's baked into our guidance that we're giving today. But if the clinical data support this and if they can stay on their production time lines, again, what we are going to continue to monitor is how they can ramp up and then continue to meet that supply requirement, as we mentioned in the late 2020 and early 2021. If Gilead continues to ramp up, if they build this international coalition, we fully expect that we will be shipping and selling more Captisol to support their campaigns.
Balaji Prasad -- Barclays -- Analyst
That's very helpful. Just leaning on that, can you help us understand how much what quantity you have shipped until now? And also on the capacity side, you had said in the past that you have adequate capacity to meet any requirements. Could you give us a sense of what is your total capacity on this? Also, is Hovione your sole contract manufacturer for Captisol? Or do you have anyone as back up?
Matthew W. Foehr -- President and Chief Operating Officer
Yes. Thanks, Balaji. Yes. So we've spoken in the past a lot of different ways to calculate capacity, but well over 100 metric tons of capacity, we've been increasing that, and we've got plans to continue to do that. We have two manufacturing plants that manufacture Captisol end-to-end. They're in the Hovione network. We are we distribute out of five distribution facilities spread out around the globe. And we are looking at involving others in manufacturing as well. So I think that probably summarizes it.
Balaji Prasad -- Barclays -- Analyst
Great. One final question on service revenue. The fact that you're breaking this out separately, should I interpret this as a statement that this will be growing meaningfully going forward? And would we assume real significance?
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Thanks, Balaji. Yes, it's a line that we'll be growing as we add new partners, but it's more stable, generally speaking, and predictable than the rest of the lines. The contracts, as I mentioned in my prepared remarks, tend to be multiyear contracts with parties. And so we have a good visibility on that year-to-year. And a large portion of it is repeat customers. Any one contract is a relatively significant portion of the business, particularly on the Vernalis and Icagen sides. And so we'll continue to monitor it and report out to customers to investors, I should say, on kind of what we see over the forward-looking 12- or 18-month period, but it will be a substantial portion of the revenue line for the foreseeable future.
Balaji Prasad -- Barclays -- Analyst
So, thanks so much.Next question.
Operator
[Operator Instructions] Your next question is from the line of Larry Solow. Your line is open.
Peter Kirk Lukas -- CJS Securities -- Analyst
Yes, hi, It's Pete Lukas for Larry. You guys covered a lot of the stuff. Just a quick one on Kyprolis. I know you mentioned the potential estimates you had there for the impact of COVID. Just wanted to know if you can comment on when we can expect Phase III data from multiple melanoma? And how much you think that could cause the target market to grow?
Matthew W. Foehr -- President and Chief Operating Officer
Yes. Thanks. You're referring to the additional Phase III data in multiple myeloma. We are seeing data that is planned to come out at ASCO. There are more Phase III data that will be presented at ASCO. Also, frontline data that is in progress. And Amgen continues to supply updates for status of those programs, and we expect that data to be coming. And they actually, recently, just last week, on their earnings call, updated that they have a November 15 PDUFA target action date for the Phase III for the CANDOR data being added to the U.S. label, and then that label is also being under review or is also under review in the EU as well.
Peter Kirk Lukas -- CJS Securities -- Analyst
Great. And then just one more for me, a general question in terms of priorities for use of cash. You mentioned in the slides, business support the business, and you touched on a few M&A opportunities. Just wondering how share buybacks would rank in that, given that you have been aggressive there but do still leave a chunk on the repurchase?
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Yes. Thanks, Pete. As we've said a few times over the last couple of quarters, when we ended up with about $1.5 billion of cash on the balance sheet, our stock price was at a place where we thought it was not particularly well valued. And so we set out on a campaign to essentially return about $0.5 billion to investors through share repurchase. And we've basically completed that having actually done closer to $600 million now. What we said coming into 2020 was we'd monitor the markets and then opportunistically buy back shares if we felt like the trading dynamics in our stock were out of whack with where we thought the fundamental business was going. Clearly, no one foresaw the COVID-19 impacts on the markets or business. But we did opportunistically buy some during Q1, as I mentioned. We'll continue to monitor as we go forward. But our focus really has mostly shifted to the M&A front. We'll still monitor both the stock and the bonds for chances to buy opportunistically. But at this point, the balance of the $750 million of cash that we think is useful for M&A, we will focus mostly on the M&A front and other product investments.
Peter Kirk Lukas -- CJS Securities -- Analyst
And I guess just on top of that, in terms of the M&A front, you mentioned a few possible candidates or areas that you'd look at. Has COVID impacted valuations there at all? Or anything different that you're seeing?
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Yes. I think COVID has impacted valuations across the board. What typically happens in a crisis like this or I should say, in a stock market decline like this is, it takes a while for Boards and managements to reset on their views of where current value is and what appropriate value is. So a lot of the ongoing M&A discussions slow down a bit and new discussions are slower to pick up. And that's what we've seen. That doesn't mean that our shopping list is any shorter or that our attempt to have these dialogues is any slower. From our standpoint, we're ready to go. But as buyer, we're in a unique position. As the sellers get more accustomed to our current values, we'll start to see the activity and ability to consummate these transactions, I think, pick up a little bit.
Lots of activity on the financing front. Our product financing effort is quite robust right now. Certainly, in a market like this, you get a lot of companies that struggle to finance themselves and end up stuck in what we've traditionally called a broken biotech, really companies that have portfolios of programs that are either unpartnered and partnerable or already partnered, we're seeing a lot of activity in that space. The larger technology platform, acquisition stuff, the larger public companies, those dialogues are ongoing but likely will take a little bit longer than before to materialize.
Peter Kirk Lukas -- CJS Securities -- Analyst
Very helpful, thank you.
Operator
Next question is from the line of Dana Flanders. your line is open.
Dana Flanders -- Guggenheim Securities, LLC -- Analyst
Hi, great, thank you for the questions. I've got a couple, if that's OK, related to Captisol. First, can you just speak to, as the just relative weighting of Captisol sales to Gilead and remdesivir increase, just what you expect that to do to the overall kind of gross margin profile of material sales this year and next year? My second question, if you could just speak to the level of investment that you're making to increase supply of Captisol, just from a cash outlay perspective? And then thirdly, and I apologize if I missed this, how much Captisol has Gilead purchased relative to that one billion kind of or one million treatment course target that they have by year-end? I mean, how much more volume does Gilead need to purchase to kind of get there?
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Thanks, Dana. I'll start on the margin question and then turn it over to Matt for some of the capital investment and supply chain stuff. I think as investors know, our P&L includes a cost of goods line that historically and, going forward, is tied only to Captisol sales. So our royalty income and our now our service revenue and our contract payment lines, all are 100% gross margin. Any of the costs associated with the service line are actually just salaries down and mostly salaries and other lab expenses that are down in R&D.
So investors can certainly track historically where our margins have been on the Captisol side, if they like. And we don't see that changing materially in the short-term from the Gilead side. Gilead has very favorable pricing from us. And we continue to believe that, going forward, the margin profile of the Captisol business will be in line with where it has been historically. What that translates to overall corporate gross margins, really just depends on where Gilead lands, where the world lands on a need for remdesivir and, ultimately, there for Captisol. I think you can do your own math. But I think if you scale up the Captisol sales to the different orders of magnitude that the production levels that Gilead is talking about might imply, you can sort of calculate the margins. I mentioned in my prepared remarks that based on what we see so far this year, we see the margin coming down from a 90% overall margin prior to this to somewhere between 85% and 90% for the overall business? And Matt, do you want to make some comments on the capital expenditure side?
Matthew W. Foehr -- President and Chief Operating Officer
Yes, sure. Yes. And on the capex, Dana, I'll just I'll generally characterize it and say it's millions of dollars, but it's an investment we're happy to make. We do not see it impacting other elements of the business or other things we want to do in the business, but it's an investment that's important and we're happy to make. As John said and as Gilead has said publicly, they're positioning to produce several million treatment courses in 2021, if required. We've got a line of sight on what may be needed. And as described, we would need to ship more material late this year and early next in order to help them do that.
Dana Flanders -- Guggenheim Securities, LLC -- Analyst
All right, thank you.
Operator
Your next question is from the line of Scott Henry. Your line is open.
Scott Henry -- ROTH Capital Partners -- Analyst
Hey, can you guys hear me?
John L. Higgins -- Chief Executive Officer
Yes, Scott.
Scott Henry -- ROTH Capital Partners -- Analyst
Hey. Just a real quick one here. So I'm looking at the Kyprolis estimates from the Amgen analyst after the quarter, and they all went up for the year. So how are you thinking about your expectations from Kyprolis royalties out of that royalty reduction? So if you're reducing here $5 million, $6 million out of that, how much are you assuming Kyprolis gets cut?
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Yes, Scott, we mentioned that we see royalties down about 15% or so. And we mentioned earlier on this year that our original estimates for Kyprolis for the year that factored into our $38 million estimate for the year were included about $1.2 billion, $1.2 billion of Kyprolis sales. So we backed that off by about 15% for the total year. I think you can compare that to the math you're running on your side and figure out where you believe we'll land.
Scott Henry -- ROTH Capital Partners -- Analyst
Thank you. Appreciate it.
Operator
[Operator Instructions] We have time for one more question. Balaji Prasad, your line is open.
Balaji Prasad -- Barclays -- Analyst
Sorry. I was on mute. Just wanted to check with you on the role of IV luminespib in treating COVID. What's the way forward and what milestones we need to look out for?
Matthew W. Foehr -- President and Chief Operating Officer
Yes. Thanks, Balaji. That it was interesting. Luminespib is a program that came to us through our acquisition of Vernalis. It's an Hsp90 inhibitor that was previously evaluated in cancer. It came up in some third-party academic screens as potentially having utility in COVID. It's we're post that publication, obviously had some inbound interest and are talking to potential collaborators, potential partners who have an interest in potentially taking that forward.
Operator
No further questions.
John L. Higgins -- Chief Executive Officer
Well, thank you. This is John Higgins. And just to wrap up, I want to thank everybody. We had a great turnout today on the call, we're seeing the people who dialed in. So appreciate your time and attention today. It's obviously a very busy time for the company. We operate in a lean business to start with. It's a very efficient corporate structure. Of course, the pandemic environment and the change to workflow, obviously, has impacted every company. And then on top of this, of course, the work that we're doing with Gilead has created a tremendous additional amount of work.
I want to thank the team. I'm really proud of this team. We're doing outstanding work. And frankly, it's inspiring to see not only the usual high level of productivity. But the team stepping up above and beyond. We have a slide inviting people to join us on Twitter. It's a simple concept, but we have so much news flow coming out of partners that it is a great way to keep track of developments. And of course, we often flag prominent new stories that relate to the remdesivir program that we link to Twitter as well. So we encourage you to sign up there. We will be at two conferences. These are virtual, but one is the Craig Hallum conference at the end of May; and then the Benchmark Healthcare conference in mid-June. And we already have very full schedules for both of those.
Thank you for calling in today, and we look forward to staying in touch as the weeks roll on.
Operator
[Operator Closing Remarks].
Duration: 62 minutes
Call participants:
Patrick O'Brien -- Senior Vice President of Investor Relations
John L. Higgins -- Chief Executive Officer
Matthew Korenberg -- Executive Vice President, Finance and Chief Financial Officer
Matthew W. Foehr -- President and Chief Operating Officer
Matt Hewitt -- Craig-Hallum Capital Group -- Analyst
Balaji Prasad -- Barclays -- Analyst
Peter Kirk Lukas -- CJS Securities -- Analyst
Dana Flanders -- Guggenheim Securities, LLC -- Analyst
Scott Henry -- ROTH Capital Partners -- Analyst
